Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CLINICAL MEASUREMENT - ANNOTATIONS

The Clinical Measurement Ontology (CMO), Measurement Methods Ontology (MMO), and Experimental Condition Ontology (XCO) are currently being developed at the Rat Genome Database. For more information about these vocabularies please see Shimoyama et al. Three ontologies to define phenotype measurement data. Front Genet. 2012;3:87. Epub 2012 May 28 or contact us (http://rgd.mcw.edu/contact/index.shtml).

Term:disease incidence/prevalence measurement
go back to main search page
Accession:CMO:0000926 term browser browse the term
Definition:Any measurement in which the number of individuals in a study population that display a disease at a point in time or develop a disease within a determined period of time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio.
Comment:Epidemiologically, incidence specifically refers to "the rate at which a certain event occurs, as the number of new cases of a specific disease occurring during a certain period in a population at risk" (Dorland), but in popular usage it can also be used as a measure of the number of individuals in a population which have a particular condition, i.e. as a synonym for prevalence.


show annotations for term's descendants           Sort by:
 
cataract incidence/prevalence measurement term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Arrd3 Age-related retinal degeneration QTL 3 IDA RGD PMID:22300709 RGD:7794750 NCBI chr 1:183,970,203...243,914,901 JBrowse link
encephalitis incidence/prevalence measurement term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Vie1 Viral induced encephalitis QTL 1 IDA RGD PMID:22761571 RGD:7240516 NCBI chr 4:34,430,484...82,490,359 JBrowse link
Q Vie2 Viral induced encephalitis QTL 2 IDA RGD PMID:22761571 RGD:7240516 NCBI chr 3:145,956,084...169,034,231 JBrowse link
Q Vie3 Viral induced encephalitis QTL 3 IDA RGD PMID:22761571 RGD:7240516 NCBI chr 6:96,833,997...140,994,061 JBrowse link
Q Vie4 Viral induced encephalitis QTL 4 IDA RGD PMID:22761571 RGD:7240516 NCBI chr 4:62,933,508...82,490,359 JBrowse link
Q Vie5 Viral induced encephalitis QTL 5 IDA RGD PMID:22761571 RGD:7240516 NCBI chr 4:34,430,484...82,490,359 JBrowse link
experimental autoimmune encephalomyelitis incidence/prevalence measurement term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Eae12 Experimental allergic encephalomyelitis QTL 12 IDA RGD PMID:10545597 RGD:69695 NCBI chr10:92,238,497...101,012,337 JBrowse link
Q Eae13 Experimental allergic encephalomyelitis QTL 13 IDA RGD PMID:10545597 RGD:69695 NCBI chr12:24,139,202...36,638,073 JBrowse link
Q Eae14 Experimental allergic encephalomyelitis QTL 14 IDA RGD PMID:10545597 RGD:69695 NCBI chr13:23,203,448...68,203,448 JBrowse link
Q Eae15 Experimental allergic encephalomyelitis QTL 15 IDA RGD PMID:10545597 RGD:69695 NCBI chr18:76,477,814...77,209,844 JBrowse link
Q Eae16 Experimental allergic encephalomyelitis QTL 16 IDA RGD PMID:12517974 RGD:629629 NCBI chr 8:8,462,195...110,921,472 JBrowse link
Q Eae17 Experimental allergic encephalomyelitis QTL 17 IDA RGD PMID:12517974 RGD:629629 NCBI chr13:8,897,350...101,631,289 JBrowse link
Q Eae2 Experimental allergic encephalomyelitis QTL 2 IDA RGD PMID:9973459 RGD:69694 NCBI chr 4:21,333,343...39,505,420 JBrowse link
Q Eae3 Experimental allergic encephalomyelitis QTL 3 IDA RGD PMID:9973459 RGD:69694 NCBI chr10:26,521,957...61,345,413 JBrowse link
Q Eae4 Experimental allergic encephalomyelitis QTL 4 IDA RGD PMID:10072499 RGD:69712 NCBI chr 9:1...25,661,317 JBrowse link
mammary tumor incidence/prevalence measurement term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Mcs31 Mammary carcinoma susceptibility QTL 31 IDA RGD PMID:23967281 RGD:7794780 NCBI chr 9:77,813,894...111,552,878 JBrowse link
Q Mcs32 Mammary carcinoma susceptibility QTL 32 IDA RGD PMID:23967281 RGD:7794780 NCBI chr 1:115,540,693...238,914,717 JBrowse link
Q Mcs33 Mammary carcinoma susceptibility QTL 33 IDA RGD PMID:23967281 RGD:7794780 NCBI chr 5:131,345,754...166,875,058 JBrowse link
Q Mcs34 Mammary carcinoma susceptibility QTL 34 IDA RGD PMID:23967281 RGD:7794780
percentage of study population developing cerebrovascular lesions during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Strs4 Sensitivity to stroke QTL 4 IDA RGD PMID:23690346 RGD:7411685 NCBI chr 1:78,430,536...123,430,536 JBrowse link
Q Strs5 Sensitivity to stroke QTL 5 IDA RGD PMID:23690346 RGD:7411685 NCBI chr18:49,999,958...65,845,095 JBrowse link
Q Strs6 Sensitivity to stroke QTL 6 IDA RGD PMID:23690346 RGD:7411685 NCBI chr 5:134,972,980...138,113,556 JBrowse link
Q Strs7 Sensitivity to stroke QTL 7 IDA RGD PMID:23690346 RGD:7411685 NCBI chr15:40,289,901...49,308,583 JBrowse link
percentage of study population developing diabetes mellitus during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Iddm15 Insulin dependent diabetes mellitus QTL 15 IDA RGD PMID:11327715 RGD:619685 NCBI chr18:60,622,311...77,209,844 JBrowse link
Q Iddm18 Insulin dependent diabetes mellitus QTL 18 IDA RGD PMID:11327715 RGD:619685 NCBI chr 6:116,506,292...130,245,370 JBrowse link
Q Iddm20 Insulin dependent diabetes mellitus QTL 20 IDA RGD PMID:15793267 RGD:1358924 NCBI chr17:13,986,773...21,975,515 JBrowse link
percentage of study population developing endometrioid carcinoma during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Edcs1 Endometrial carcinoma susceptibility QTL1 IDA RGD PMID:11745480 RGD:1599856 NCBI chr11:18,976,208...24,697,116 JBrowse link
Q Edcs2 Endometrial carcinoma susceptibility QTL2 IDA RGD PMID:11745480 RGD:1599856 NCBI chr12:6,833,190...17,870,186 JBrowse link
Q Edcs3 Endometrial carcinoma susceptibility QTL3 IDA RGD PMID:11745480 RGD:1599856 NCBI chr20:1...25,159,026 JBrowse link
Q Edcs4 Endometrial carcinoma susceptibility QTL 4 IDA RGD PMID:11745480 RGD:1599856 NCBI chr 1:206,081,677...251,081,677 JBrowse link
Q Edcs5 Endometrial carcinoma susceptibility QTL 5 IDA RGD PMID:11745480 RGD:1599856 NCBI chr17:57,246,723...70,852,846 JBrowse link
percentage of study population developing experimental autoimmune encephalomyelitis during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Eae20 Experimental allergic encephalomyelitis QTL 20 IDA RGD PMID:15634914 RGD:1547849 NCBI chr 4:153,031,106...158,841,762 JBrowse link
Q Eae24 Experimental allergic encephalomyelitis QTL 24 IDA RGD PMID:19675581 RGD:2317591 NCBI chr 4:66,993,185...72,752,834 JBrowse link
Q Eae25 Experimental allergic encephalomyelitis QTL 25 IDA RGD PMID:19675581 RGD:2317591 NCBI chr 4:78,882,817...83,007,655 JBrowse link
Q Eae27 Experimental allergic encephalomyelitis QTL 27 IDA RGD PMID:19675581 RGD:2317591 NCBI chr 4:103,194,805...112,478,794 JBrowse link
Q Eae8 Experimental allergic encephalomyelitis QTL 8 IDA RGD PMID:10640775 RGD:61031 NCBI chr19:24,816,041...33,061,905 JBrowse link
percentage of study population developing mammary tumors during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Emca4 Estrogen-induced mammary cancer QTL 4 IDA RGD PMID:16885383 RGD:1642522 NCBI chr 7:62,004,452...101,773,158 JBrowse link
Q Emca5 Estrogen-induced mammary cancer QTL 5 IDA RGD PMID:16885383 RGD:1642522 NCBI chr 3:43,827,364...169,034,231 JBrowse link
percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Eae10 Experimental allergic encephalomyelitis QTL 10 IDA RGD PMID:10640775 RGD:61031 NCBI chr14:17,622,685...18,274,498 JBrowse link
Q Eae5 Experimental allergic encephalomyelitis QTL 5 IDA RGD PMID:10640775 RGD:61031 NCBI chr12:19,610,870...46,669,029 JBrowse link
percentage of study population developing retinopathy during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Arrd1 Age-related retinal degeneration QTL 1 IDA RGD PMID:22300709 RGD:7794750 NCBI chr 1:100,357,752...183,970,443 JBrowse link
Q Arrd2 Age-related retinal degeneration QTL 2 IDA RGD PMID:22300709 RGD:7794750 NCBI chr 1:183,970,203...243,914,901 JBrowse link
percentage of study population developing T-cell lymphomas during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Tls2 T-lymphoma susceptibility QTL 2 IDA RGD PMID:10360666 RGD:619600 NCBI chr 7:80,221,299...109,401,111 JBrowse link
Q Tls3 T-lymphoma susceptibility QTL 3 IDA RGD PMID:10360666 RGD:619600 NCBI chr10:51,774,612...95,600,334 JBrowse link
percentage of study population developing testis tumors during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Tescar1 Testicular tumor resistance QTL 1 IDA RGD PMID:15805257 RGD:1358944 NCBI chr11:1,041,931...66,113,562 JBrowse link
percentage of study population developing trigeminal nerve neurilemmomas during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Schws1 Schwannoma susceptibility QTL 1 IDA RGD PMID:16003739 RGD:1559300 NCBI chr10:40,035,094...102,359,817 JBrowse link
Q Schws2 Schwannoma susceptibility QTL 2 IDA RGD PMID:16003739 RGD:1559300
Q Schws3 Schwannoma susceptibility QTL 3 IDA RGD PMID:16003739 RGD:1559300 NCBI chr 3:118,839,124...163,839,124 JBrowse link
Q Schws4 Schwannoma susceptibility QTL 4 IDA RGD PMID:16003739 RGD:1559300 NCBI chr 6:83,190,345...106,747,639 JBrowse link
Q Schws7 Schwannoma susceptibility QTL 7 IDA RGD PMID:16003739 RGD:1559300 NCBI chr10:4,765,527...19,816,042 JBrowse link
Q Schws8 Schwannoma susceptibility QTL 8 IDA RGD PMID:25303613 RGD:11566050 NCBI chr 6:94,968,928...139,968,928 JBrowse link
Q Schws9 Schwannoma susceptibility QTL 9 IDA RGD PMID:25303613 RGD:11566050 NCBI chr 6:61,747,639...106,747,639 JBrowse link
percentage of study population developing unilateral renal agenesis during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Renag1 Renal agenesis QTL 1 IDA RGD PMID:16845468 RGD:1580355 NCBI chr14:8,170,668...68,298,175 JBrowse link
percentage of study population developing ventral prostate tumorous lesions during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Prcs1 Prostate cancer susceptibility QTL 1 IDA RGD PMID:15805257 RGD:1358944 NCBI chr19:15,114,598...34,521,833 JBrowse link
Q Prcs2 Prostate cancer susceptibility QTL 2 IDA RGD PMID:15805257 RGD:1358944 NCBI chr20:4,606,607...17,617,956 JBrowse link
percentage of study population displaying chronic pancreatitis at a point in time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Panci1 Pancreas inflammation QTL 1 IDA RGD PMID:11414764 RGD:619682 NCBI chr 7:116,677,189...127,103,496 JBrowse link
percentage of study population displaying Toxoplasma gondii brain cysts at a point in time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Toxo1 Toxoplasma gondii resistance QTL 1 IDA RGD PMID:16407112 RGD:1578521 NCBI chr10:52,200,030...59,378,278 JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  clinical measurement 2369
    disease population measurement 57
      disease incidence/prevalence measurement 57
        alimentary/gastrointestinal disease incidence/prevalence measurement + 0
        arthritis incidence/prevalence measurement + 0
        cataract incidence/prevalence measurement + 1
        chronic pancreatitis incidence/prevalence measurement + 1
        congenital malformation incidence/prevalence measurement + 1
        diabetes mellitus incidence/prevalence measurement + 3
        endometrioid carcinoma incidence/prevalence measurement + 5
        glycosuria incidence/prevalence measurement + 0
        hematuria incidence/prevalence measurement + 0
        infection incidence/prevalence measurement + 1
        leukemia incidence/prevalence measurement + 0
        lymphoma incidence/prevalence measurement + 2
        nervous system disease incidence/prevalence measurement + 25
        organ non-tumorous lesion incidence/prevalence measurement + 4
        organ tumorous lesion incidence/prevalence measurement + 18
        percentage of study population developing ascites during a period of time 0
        percentage of study population developing extra-hepatic metastases during a period of time 0
        percentage of study population developing peritoneal carcinomatosis during a period of time 0
        percentage of study population developing radiation pneumonitis during a period of time 0
        percentage of study population developing radiation-induced bone marrow disease during a period of time 0
        pyometritis incidence/prevalence measurement + 0
        retinopathy incidence/prevalence measurement + 2
paths to the root